ARTICLE | Clinical News
Selonsertib: Phase II data
October 31, 2016 7:00 AM UTC
Top-line data from the open-label, North American Phase II Study GS-US-384-1497 in 67 evaluable patients with NASH and moderate to severe liver fibrosis showed that once-daily 6 and 18 mg selonsertib ...